# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9035 in Healthy Adult Volunteers and Mildly Hypertensive Participants

> **NCT05291546** · PHASE1 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 93 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** REGN9035
- **DRUG:** REGN5381
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05291546
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-13
- **Primary completion:** 2024-04-02
- **Final completion:** 2024-04-02
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2024-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05291546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05291546, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9035 in Healthy Adult Volunteers and Mildly Hypertensive Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05291546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*